MANTECH Publications

Journal of Pharmacovigilance and Quality Assurance
Volume 2, Issue 1, January-June, 2020

Global Pharmacovigilance Databases (VigiBase, FAERS, EudraVigilance): Enhancing Drug Safety Monitoring

Dr. Neha Joshi
Associate Professor
Department of Pharmacology
Bangalore College of Pharmacy, Bangalore, India
Email: *neha.joshi.research@gmail.com*

Mr. Aditya Singh
Research Scholar
Department of Clinical Pharmacy
Delhi Institute of Pharmaceutical Sciences, Delhi, India
Email: *aditya.singh_scholar@yahoo.co.in*

ABSTRACT

*Global pharmacovigilance databases, including VigiBase, FAERS, and EudraVigilance, play a crucial role in monitoring drug safety across populations. These repositories collect and analyze adverse drug reactions (ADRs) reported by healthcare professionals, patients, and manufacturers. This paper discusses the structure, functionalities, and impact of these databases on drug safety surveillance, signal detection, and regulatory decision-making. It also highlights the challenges, such as data standardization, underreporting, and integration with national pharmacovigilance systems. Tables summarizing database characteristics and reporting metrics are included. Effective utilization of global pharmacovigilance databases enhances patient safety, informs regulatory actions, and supports the rational use of medicines worldwide.**

KEYWORDS: *Pharmacovigilance, VigiBase, FAERS, EudraVigilance, Adverse Drug Reactions, Drug Safety, Signal Detection*

INTRODUCTION

Pharmacovigilance is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. Global pharmacovigilance databases enable the collection, analysis, and sharing of adverse drug reaction (ADR) data from multiple countries, providing critical insights into drug safety and informing regulatory actions. VigiBase, FAERS, and EudraVigilance are prominent international databases that play a vital role in monitoring medicine safety on a global scale.

These databases support healthcare systems by providing structured information on ADRs, facilitating early identification of safety signals, and promoting evidence-based decisions for drug approval, withdrawal, or labeling updates. They also allow regulators, researchers, and pharmaceutical companies to assess risk-benefit profiles of medicines and enhance public trust in pharmacotherapy.

VIGIBASE

VigiBase, maintained by the Uppsala Monitoring Centre (UMC) under the World Health Organization (WHO), collects ADR reports from over 140 member countries. It uses standardized medical terminologies such as MedDRA to facilitate signal detection and analysis. VigiBase supports early identification of safety signals, enabling timely regulatory interventions and dissemination of safety information.

The database contains millions of Individual Case Safety Reports (ICSRs), covering a wide spectrum of drugs, patient demographics, and reported reactions. VigiBase allows comprehensive statistical analyses and employs algorithms to detect disproportional reporting, thus identifying potential safety concerns that may require further investigation.

FAERS

The FDA Adverse Event Reporting System (FAERS) is a US-based database that collects spontaneous reports of adverse events and medication errors. FAERS data are used for monitoring post-marketing drug safety, detecting potential risks, and informing label changes or safety warnings.

FAERS contains reports submitted by healthcare professionals, patients, and manufacturers and is continuously updated. The database allows regulators and researchers to analyze trends, evaluate the safety profile of medications in the US market, and support regulatory decisions for both prescription and over-the-counter drugs.

EUDRAVIGILANCE

EudraVigilance is the European Union's system for managing and analyzing information on suspected adverse reactions to medicines authorized in the European Economic Area (EEA). It facilitates the collection, management, and evaluation of ADR reports, supports signal detection, and provides data to competent authorities for risk assessment and regulatory decision-making.

EudraVigilance integrates with national pharmacovigilance programs to provide harmonized data across EU member states. The system enables timely identification of safety concerns, issuance of warnings, and implementation of measures to protect public health.

METHODOLOGIES IN GLOBAL PHARMACOVIGILANCE

Global pharmacovigilance databases rely on multiple methodologies to ensure effective drug safety monitoring:

1. **Spontaneous Reporting:** Collection of ADRs from healthcare professionals, patients, and pharmaceutical companies.
2. **Periodic Safety Update Reports (PSURs):** Manufacturers submit safety data for regulatory review.
3. **Literature Monitoring:** Published case reports and studies are incorporated into databases.
4. **Electronic Health Records (EHRs):** Real-time monitoring of ADRs through integration with hospital and clinical data.

Advanced statistical algorithms, data mining techniques, and disproportionality analyses are employed to detect emerging safety signals. The combination of spontaneous and systematic surveillance ensures robust pharmacovigilance globally.

CHALLENGES IN GLOBAL DATABASES

Despite their utility, global pharmacovigilance databases face several challenges:

- **Underreporting:** Many ADRs remain unreported due to lack of awareness or perceived insignificance.
- **Data Quality:** Inconsistent or incomplete reports reduce the reliability of analyses.
- **Standardization Issues:** Differences in terminologies and coding can affect data interpretation.
- **Duplicate Reports:** Multiple submissions for the same event can skew statistics.
- **Integration Limitations:** Linking national and global databases requires standardized data formats and harmonized reporting guidelines.

Addressing these challenges requires enhanced training, international collaboration, adoption of standard terminologies, and improved digital tools for data capture and analysis.

TABLES

Table 1: Characteristics of Global Pharmacovigilance Databases

Database	Maintained By	Region/Coverage	Reports (Approx.)
VigiBase	Uppsala Monitoring Centre (WHO)	Global (140+ countries)	20 million+
FAERS	US FDA	United States	15 million+
EudraVigilance	European Medicines Agency	European Economic Area	10 million+

Table 1: Characteristics of major global pharmacovigilance databases.

Table 2: Reporting Metrics and Applications

Database	Type of Reports	Reporting Frequency	Primary Use
VigiBase	Spontaneous ADRs, literature, periodic reports	Continuous	Signal detection, global risk assessment
FAERS	Spontaneous ADRs, medication errors	Quarterly	Post-marketing safety, label updates

Database	Type of Reports	Reporting Frequency	Primary Use
EudraVigilance	Suspected ADRs, PSURs	Continuous	Regulatory assessment, safety signal detection

Table 2: Reporting metrics and applications of global pharmacovigilance databases.

SIGNIFICANCE OF GLOBAL PHARMACOVIGILANCE DATABASES

Global pharmacovigilance databases enhance patient safety by providing early warning of potential drug-related risks. They allow regulators to issue timely advisories, modify drug labels, and recommend withdrawal of harmful medicines. For pharmaceutical companies, these databases support risk management, guide post-marketing surveillance, and inform future drug development.

Moreover, international collaboration enables sharing of best practices, harmonization of safety standards, and strengthening of national pharmacovigilance programs. The integration of digital technologies and real-world data further improves the scope and accuracy of safety monitoring.

CONCLUSION

Global pharmacovigilance databases such as VigiBase, FAERS, and EudraVigilance are indispensable for monitoring drug safety, detecting signals, and guiding regulatory decisions. They facilitate international collaboration, enhance patient safety, and support evidence-based decision-making in pharmacotherapy.

Despite challenges such as data standardization and underreporting, effective utilization of these databases ensures timely identification of risks, promotes rational drug use, and strengthens global pharmacovigilance efforts. Continued investment in digital tools, harmonized reporting standards, and awareness programs will enhance the utility and reliability of these systems worldwide.

REFERENCES

1. WHO. *VigiBase: The WHO Global ICSR Database System.* UMC, 2021.
2. US FDA. *FDA Adverse Event Reporting System (FAERS).* FDA, 2020.
3. European Medicines Agency. *EudraVigilance.* EMA, 2021.
4. Li Q, et al. *Global pharmacovigilance databases and drug safety.* Drug Saf, 2019.
5. Uppsala Monitoring Centre. *Signal detection in VigiBase.* WHO, 2018.
6. Smith J, et al. *Analysis of FAERS data for post-marketing surveillance.* Clin Pharmacol Ther, 2020.
7. European Medicines Agency. *Pharmacovigilance and signal management.* EMA, 2019.
8. Khan M, et al. *Comparative study of global ADR databases.* J Pharm Regul Sci, 2021.